AKT1 and systemic lupus erythematosus: For moderate and severe SLE, hUC‐MSCs effectively inhibit pro‐inflammatory milieu to promote disease remission by decreasing the expression of HSP90AA1 in the PI3K‐AKT pathway induced by CD4+T cell glucose metabolic activation.